Pascal Auquier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pascal Auquier has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- C. Lançon
Pôle de psychiatrie universitaire, hôpital Sainte-Marguerite, 270, boulevard de Sainte-Marguerite, 13274 Marseille cedex 9, France; Unité de recherche santé perçue, université d'Aix-Marseille, EA 3279, 13005 Marseille, France
12 shared publications C Manuel
11 shared publicationsL. Boyer
Unité de recherche santé perçue, université d'Aix-Marseille, EA 3279, 13005 Marseille, France
6 shared publicationsD Reviron
5 shared publications- Fabrice Barleísi
Oncologie Thoracique, Faculté de Médecine Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille
5 shared publications J L San Marco
5 shared publications
Latest Publications
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A659
Potential Funding Sources For Breakthrough Therapies
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A659
Potential Funding Sources For Breakthrough Therapies
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A672
Could Healthcoin Be A Revolution In Healthcare?
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A672
Could Healthcoin Be A Revolution In Healthcare?
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi419
Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC): the French IFCT-PREDICT.amm study
Background: Knowledge of molecular status improves the clinical benefit of targeted therapies. ALK rearrangement and EGFR/KRAS mutation are the main biomarkers tested to deliver or not targeted therapies in advanced NSCLC, but their economic impact has not been studied in large prospective cohorts. One objective of the IFCT-PREDICT.amm study was to evaluate the incremental cost-effectiveness ratio (ICER) of a strategy including the knowledge of at least one biomarker status at first- or second-line and the most appropriate treatment (intervention strategy) compared with the standard of care without biomarker testing (reference strategy).
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi419
Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC): the French IFCT-PREDICT.amm study
Background: Knowledge of molecular status improves the clinical benefit of targeted therapies. ALK rearrangement and EGFR/KRAS mutation are the main biomarkers tested to deliver or not targeted therapies in advanced NSCLC, but their economic impact has not been studied in large prospective cohorts. One objective of the IFCT-PREDICT.amm study was to evaluate the incremental cost-effectiveness ratio (ICER) of a strategy including the knowledge of at least one biomarker status at first- or second-line and the most appropriate treatment (intervention strategy) compared with the standard of care without biomarker testing (reference strategy).
- 1 November 2015
- Published by Elsevier in Value in Health
- Vol. 18 (7) , A518-A519
Market Access of Atmps: Overview and Expected Challenges
- 1 November 2015
- Published by Elsevier in Value in Health
- Vol. 18 (7) , A518-A519
Market Access of Atmps: Overview and Expected Challenges
- 1 May 2015
- Published by Elsevier in Archives de Pédiatrie
- Vol. 22 (5) , 378
Prix SFP 2013 – 2 – Qualité de vie des extrêmes prématurés en âge scolaire: Troubles Neurologiques Mineurs
- 1 May 2015
- Published by Elsevier in Archives de Pédiatrie
- Vol. 22 (5) , 378
Prix SFP 2013 – 2 – Qualité de vie des extrêmes prématurés en âge scolaire: Troubles Neurologiques Mineurs
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A567
Assessment Of The Huntington Quality Of Life Instrument (H-QOL-I) Cross-Cultural Validity
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A567
Assessment Of The Huntington Quality Of Life Instrument (H-QOL-I) Cross-Cultural Validity
- 1 February 2014
- Published by Elsevier in L'Encéphale
- Vol. 40 (1) , 74-80
Qualité de vie liée à la santé dans la dépression après stimulation magnétique transcrânienne basse fréquence
- 1 February 2014
- Published by Elsevier in L'Encéphale
- Vol. 40 (1) , 74-80
Qualité de vie liée à la santé dans la dépression après stimulation magnétique transcrânienne basse fréquence
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A325-A326
PND46 The Huntington Quality of Life Instrument (H-QOL-I): Cross-Cultural Validation in Germany, Poland and USA
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A325-A326
PND46 The Huntington Quality of Life Instrument (H-QOL-I): Cross-Cultural Validation in Germany, Poland and USA
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A296
PMH54 Quality of Life as a Predictor of Clinical Outcome: Example in Schizophrenia
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A296
PMH54 Quality of Life as a Predictor of Clinical Outcome: Example in Schizophrenia